HIGHLIGHTS
- who: Donatella Gambini and Elisabetta Kuhn from the Ospedale Maggiore Policlinico, Milan, Italy have published the paper: Basal Cell Carcinoma and Hedgehog Pathway Inhibitors: Focus on Immune Response, in the Journal: (JOURNAL)
SUMMARY
Basal cell carcinoma (BCC) is the most common form of skin cancer, with predominantly local malignancy. Given the high incidence of BCC in immunocompromised patients, some studies were conducted to understand the local immune_response elicited by the tumor, as well as the immunological modifications consequent to Hh pathway inhibition therapy. In this review, the authors summarize the main features of . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.